|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 92 No. 4 (August 15), 1998:
pp. 1165-1171
Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia
(CLL) Receiving Fludarabine Regimens as Initial Therapy
M.J. Keating,
S. O'Brien,
S. Lerner,
C. Koller,
M. Beran,
L.E. Robertson,
E. J Freireich,
E. Estey, and
H. Kantarjian
From the Department of Hematology, The University of Texas, M.D.
Anderson Cancer Center, Houston, TX.
One hundred seventy-four patients with progressive or advanced
chronic lymphocytic leukemia (CLL) have received initial therapy with
fludarabine as a single agent or fludarabine combined with prednisone.
The overall response rate was 78% and the median survival was 63 months. No difference in response rate or survival was noted in the 71 patients receiving fludarabine as a single agent compared with the 103 patients who received prednisone in addition. The median time to
progression of responders was 31 months and the overall median survival
was 74 months. Patients over the age of 70 years had shorter survivals.
Patients with advanced stage disease (Rai III and IV) had a somewhat
shorter survival than earlier stage patients. More than half the
patients who relapsed after fludarabine therapy responded to salvage
treatment, usually with fludarabine-based regimens. Second remissions
were more common in patients who had achieved a complete remission on
their initial treatment. The CD4 and CD8 T-lymphocyte subpopulations
decreased to levels in the range of 150 to 200/µL after the first 3 courses of treatment. Although recovery towards normal levels was slow, the incidence of infections was low in patients in remission (1 episode
of infection for every 3.33 patient years at risk) and decreased with
time off treatment. There was no association of infections or febrile
episodes with the use of corticosteroids or the CD4 count at the end of
treatment and a poor correlation with the increase in CD4 counts during
remission. Infectious episodes were less common in patients who had a
complete response compared with partial responders. Richter's
transformation occurred in 9 patients and Hodgkin's disease occurred
in 4 patients. Five other patients died from other second malignancies.
Fludarabine appears to be an effective initial induction therapy with a
reasonable safety profile for patients with CLL.
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
W. G. Wierda, S. O'Brien, X. Wang, S. Faderl, A. Ferrajoli, K.-A. Do, G. Garcia-Manero, J. Cortes, D. Thomas, C. Koller, et al.
Characteristics Associated With Important Clinical End Points in Patients With Chronic Lymphocytic Leukemia at Initial Treatment
J. Clin. Oncol.,
April 1, 2009;
27(10):
1637 - 1643.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Tam, S. O'Brien, W. Wierda, H. Kantarjian, S. Wen, K.-A. Do, D. A. Thomas, J. Cortes, S. Lerner, and M. J. Keating
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
Blood,
August 15, 2008;
112(4):
975 - 980.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Tsimberidou, W. G. Wierda, W. Plunkett, R. Kurzrock, S. O'Brien, S. Wen, A. Ferrajoli, F. Ravandi-Kashani, G. Garcia-Manero, Z. Estrov, et al.
Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
January 10, 2008;
26(2):
196 - 203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Bosch, A. Ferrer, N. Villamor, M. Gonzalez, J. Briones, E. Gonzalez-Barca, E. Abella, S. Gardella, L. Escoda, E. Perez-Ceballos, et al.
Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication
Clin. Cancer Res.,
January 1, 2008;
14(1):
155 - 161.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Lichtman, H. Wildiers, E. Chatelut, C. Steer, D. Budman, V. A. Morrison, B. Tranchand, I. Shapira, and M. Aapro
International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patients--An Analysis of the Medical Literature
J. Clin. Oncol.,
May 10, 2007;
25(14):
1832 - 1843.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. O'Brien, J. O. Moore, T. E. Boyd, L. M. Larratt, A. Skotnicki, B. Koziner, A. A. Chanan-Khan, J. F. Seymour, R. G. Bociek, S. Pavletic, et al.
Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
March 20, 2007;
25(9):
1114 - 1120.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Nimmanapalli, M.-A. Lyu, M. Du, M. J. Keating, M. G. Rosenblum, and V. Gandhi
The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells
Blood,
March 15, 2007;
109(6):
2557 - 2564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. A. Morrison
Management of Infectious Complications in Patients with Chronic Lymphocytic Leukemia
Hematology,
January 1, 2007;
2007(1):
332 - 338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. W. L. Yee and S. M. O'Brien
Chronic Lymphocytic Leukemia: Diagnosis and Treatment
Mayo Clin. Proc.,
August 1, 2006;
81(8):
1105 - 1129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. I. Del Principe, G. Del Poeta, F. Buccisano, L. Maurillo, A. Venditti, A. Zucchetto, R. Marini, P. Niscola, M. A. I. Consalvo, C. Mazzone, et al.
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia
Blood,
August 1, 2006;
108(3):
853 - 861.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sandherr, H. Einsele, H. Hebart, C. Kahl, W. Kern, M. Kiehl, G. Massenkeil, O. Penack, X. Schiel, S. Schuettrumpf, et al.
Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO)
Ann. Onc.,
July 1, 2006;
17(7):
1051 - 1059.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Lamanna, M. Kalaycio, P. Maslak, J. G. Jurcic, M. Heaney, R. Brentjens, A. D. Zelenetz, D. Horgan, A. Gencarelli, K. S. Panageas, et al.
Pentostatin, Cyclophosphamide, and Rituximab Is an Active, Well-Tolerated Regimen for Patients With Previously Treated Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
April 1, 2006;
24(10):
1575 - 1581.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Delgado, K. Thomson, N. Russell, J. Ewing, W. Stewart, G. Cook, S. Devereux, R. Lovell, R. Chopra, D. I. Marks, et al.
Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study
Blood,
February 15, 2006;
107(4):
1724 - 1730.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. F. Eichhorst, R. Busch, G. Hopfinger, R. Pasold, M. Hensel, C. Steinbrecher, S. Siehl, U. Jager, M. Bergmann, S. Stilgenbauer, et al.
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
Blood,
February 1, 2006;
107(3):
885 - 891.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. G. Wierda
Current and Investigational Therapies for Patients with CLL
Hematology,
January 1, 2006;
2006(1):
285 - 294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. L. Abbott
Chronic Lymphocytic Leukemia: Recent Advances in Diagnosis and Treatment
Oncologist,
January 1, 2006;
11(1):
21 - 30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. L. Kasamon, I. W. Flinn, M. R. Grever, L. F. Diehl, E. Garrett-Mayer, S. N. Goodman, M. S. Lucas, and J. C. Byrd
Phase I Study of Low-Dose Interleukin-2, Fludarabine, and Cyclophosphamide for Previously Untreated Indolent Lymphoma and Chronic Lymphocytic Leukemia
Clin. Cancer Res.,
December 1, 2005;
11(23):
8413 - 8417.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Chanan-Khan, K. C. Miller, K. Takeshita, A. Koryzna, K. Donohue, Z. P. Bernstein, A. Mohr, D. Klippenstein, P. Wallace, J. B. Zeldis, et al.
Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)
Blood,
November 15, 2005;
106(10):
3348 - 3352.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Caballero, J. A. Garcia-Marco, R. Martino, V. Mateos, J. M. Ribera, J. Sarra, A. Leon, G. Sanz, J. de la Serna, R. Cabrera, et al.
Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q- and 17p-)
Clin. Cancer Res.,
November 1, 2005;
11(21):
7757 - 7763.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Elter, P. Borchmann, H. Schulz, M. Reiser, S. Trelle, R. Schnell, M. Jensen, P. Staib, T. Schinkothe, H. Stutzer, et al.
Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial
J. Clin. Oncol.,
October 1, 2005;
23(28):
7024 - 7031.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Balakrishnan, W. G. Wierda, M. J. Keating, and V. Gandhi
Mechanisms of Cell Death of Chronic Lymphocytic Leukemia Lymphocytes by RNA-Directed Agent, 8-NH2-Adenosine
Clin. Cancer Res.,
September 15, 2005;
11(18):
6745 - 6752.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Keating, S. O'Brien, M. Albitar, S. Lerner, W. Plunkett, F. Giles, M. Andreeff, J. Cortes, S. Faderl, D. Thomas, et al.
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
June 20, 2005;
23(18):
4079 - 4088.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. F Kisor
Nelarabine: A Nucleoside Analog with Efficacy in T-Cell and Other Leukemias
Ann. Pharmacother.,
June 1, 2005;
39(6):
1056 - 1063.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Balakrishnan, C. M. Stellrecht, D. Genini, M. Ayres, W. G. Wierda, M. J. Keating, L. M. Leoni, and V. Gandhi
Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP
Blood,
June 1, 2005;
105(11):
4455 - 4462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Moreton, B. Kennedy, G. Lucas, M. Leach, S. M.B. Rassam, A. Haynes, J. Tighe, D. Oscier, C. Fegan, A. Rawstron, et al.
Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival
J. Clin. Oncol.,
May 1, 2005;
23(13):
2971 - 2979.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.S. Czuczman, A. Koryzna, A. Mohr, C. Stewart, K. Donohue, L. Blumenson, Z.P. Bernstein, P. McCarthy, A. Alam, F. Hernandez-Ilizaliturri, et al.
Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma
J. Clin. Oncol.,
February 1, 2005;
23(4):
694 - 704.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Faderl, V. Gandhi, S. O'Brien, P. Bonate, J. Cortes, E. Estey, M. Beran, W. Wierda, G. Garcia-Manero, A. Ferrajoli, et al.
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias
Blood,
February 1, 2005;
105(3):
940 - 947.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Milligan, S. Fernandes, R. Dasgupta, F. E. Davies, E. Matutes, C. D. Fegan, C. McConkey, J. A. Child, D. Cunningham, G. J. Morgan, et al.
Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses
Blood,
January 1, 2005;
105(1):
397 - 404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Dreger, S. Stilgenbauer, A. Benner, M. Ritgen, A. Krober, M. Kneba, N. Schmitz, and H. Dohner
The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status
Blood,
April 1, 2004;
103(7):
2850 - 2858.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Muller, G. Tsakou, F. Grunebach, S. M. Schmidt, and P. Brossart
Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells
Blood,
March 1, 2004;
103(5):
1763 - 1769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. T. Jones, E. Addison, J. M. North, M. W. Lowdell, A. V. Hoffbrand, A. B. Mehta, K. Ganeshaguru, N. I. Folarin, and R. G. Wickremasinghe
Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs
Blood,
March 1, 2004;
103(5):
1855 - 1861.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Gandhi, H. Kantarjian, S. Faderl, P. Bonate, M. Du, M. Ayres, M. B. Rios, M. J. Keating, and W. Plunkett
Pharmacokinetics and Pharmacodynamics of Plasma Clofarabine and Cellular Clofarabine Triphosphate in Patients with Acute Leukemias
Clin. Cancer Res.,
December 15, 2003;
9(17):
6335 - 6342.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. Astrow
Fludarabine-Related Myeloid Leukemia
J. Clin. Oncol.,
October 1, 2003;
21(19):
3709 - 3709.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. A. Morrison
In Reply:
J. Clin. Oncol.,
October 1, 2003;
21(19):
3709 - 3710.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Pahler, S. Ruiz, I. Niemer, L. R. Calvert, M. Andreeff, M. Keating, S. Faderl, and D. J. McConkey
Effects of the Proteasome Inhibitor, Bortezomib, on Apoptosis in Isolated Lymphocytes Obtained from Patients with Chronic Lymphocytic Leukemia
Clin. Cancer Res.,
October 1, 2003;
9(12):
4570 - 4577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kantarjian, V. Gandhi, J. Cortes, S. Verstovsek, M. Du, G. Garcia-Manero, F. Giles, S. Faderl, S. O'Brien, S. Jeha, et al.
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia
Blood,
October 1, 2003;
102(7):
2379 - 2386.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. A. Rao and W. Plunkett
Activation of a p53-mediated Apoptotic Pathway in Quiescent Lymphocytes after the Inhibition of DNA Repair by Fludarabine
Clin. Cancer Res.,
August 1, 2003;
9(8):
3204 - 3212.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bornhauser, B. Storer, J. T. Slattery, F. R. Appelbaum, H. J. Deeg, J. Hansen, P. J. Martin, G. B. McDonald, W. G. Nichols, J. Radich, et al.
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells
Blood,
August 1, 2003;
102(3):
820 - 826.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Schetelig, C. Thiede, M. Bornhauser, R. Schwerdtfeger, M. Kiehl, J. Beyer, H.G. Sayer, N. Kroger, M. Hensel, C. Scheffold, et al.
Evidence of a Graft-Versus-Leukemia Effect in Chronic Lymphocytic Leukemia After Reduced-Intensity Conditioning and Allogeneic Stem-Cell Transplantation: The Cooperative German Transplant Study Group
J. Clin. Oncol.,
July 15, 2003;
21(14):
2747 - 2753.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Anether, I. Tinhofer, M. Senfter, and R. Greil
Tetrocarcin-A--induced ER stress mediates apoptosis in B-CLL cells via a Bcl-2--independent pathway
Blood,
June 1, 2003;
101(11):
4561 - 4568.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Hainsworth, S. Litchy, J. H. Barton, G. A. Houston, R. C. Hermann, J. E. Bradof, and F. A. Greco
Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network
J. Clin. Oncol.,
May 1, 2003;
21(9):
1746 - 1751.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. N. O'Brien, N. M.A. Blijlevens, T. H. Mahfouz, and E. J. Anaissie
Infections in Patients with Hematological Cancer: Recent Developments
Hematology,
January 1, 2003;
2003(1):
438 - 472.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. A. Morrison, K. R. Rai, B. L. Peterson, J. E. Kolitz, L. Elias, F. R. Appelbaum, J. D. Hines, L. Shepherd, R. A. Larson, and C. A. Schiffer
Therapy-Related Myeloid Leukemias Are Observed in Patients With Chronic Lymphocytic Leukemia After Treatment With Fludarabine and Chlorambucil: Results of an Intergroup Study, Cancer and Leukemia Group B 9011
J. Clin. Oncol.,
September 15, 2002;
20(18):
3878 - 3884.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Keating, I. Flinn, V. Jain, J.-L. Binet, P. Hillmen, J. Byrd, M. Albitar, L. Brettman, P. Santabarbara, B. Wacker, et al.
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
Blood,
May 15, 2002;
99(10):
3554 - 3561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Yamauchi, B. J. Nowak, M. J. Keating, and W. Plunkett
DNA Repair Initiated in Chronic Lymphocytic Leukemia Lymphocytes by 4-Hydroperoxycyclophosphamide Is Inhibited by Fludarabine and Clofarabine
Clin. Cancer Res.,
November 1, 2001;
7(11):
3580 - 3589.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Del Poeta, L. Maurillo, A. Venditti, F. Buccisano, A. M. Epiceno, G. Capelli, A. Tamburini, G. Suppo, A. Battaglia, M. I. Del Principe, et al.
Clinical significance of CD38 expression in chronic lymphocytic leukemia
Blood,
November 1, 2001;
98(9):
2633 - 2639.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Leporrier, S. Chevret, B. Cazin, N. Boudjerra, P. Feugier, B. Desablens, M.-J. Rapp, J. Jaubert, C. Autrand, M. Divine, et al.
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients
Blood,
October 15, 2001;
98(8):
2319 - 2325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. A. Morrison, K. R. Rai, B. L. Peterson, J. E. Kolitz, L. Elias, F. R. Appelbaum, J. D. Hines, L. Shepherd, R. E. Martell, R. A. Larson, et al.
Impact of Therapy With Chlorambucil, Fludarabine, or Fludarabine Plus Chlorambucil on Infections in Patients With Chronic Lymphocytic Leukemia: Intergroup Study Cancer and Leukemia Group B 9011
J. Clin. Oncol.,
August 15, 2001;
19(16):
3611 - 3621.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Granziero, P. Ghia, P. Circosta, D. Gottardi, G. Strola, M. Geuna, L. Montagna, P. Piccoli, M. Chilosi, and F. Caligaris-Cappio
Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia
Blood,
May 1, 2001;
97(9):
2777 - 2783.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Gandhi, W. Plunkett, S. Weller, M. Du, M. Ayres, C. O. Rodriguez Jr, P. Ramakrishna, G. L. Rosner, J. P. Hodge, S. O'Brien, et al.
Evaluation of the Combination of Nelarabine and Fludarabine in Leukemias: Clinical Response, Pharmacokinetics, and Pharmacodynamics in Leukemia Cells
J. Clin. Oncol.,
April 15, 2001;
19(8):
2142 - 2152.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Azuma, P. Huang, A. Matsuda, and W. Plunkett
2'-C-Cyano-2'-deoxy-1-{beta}-D-arabino-pentofuranosylcytosine: A Novel Anticancer Nucleoside Analog that Causes Both DNA Strand Breaks and G2 Arrest
Mol. Pharmacol.,
April 1, 2001;
59(4):
725 - 731.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. M. O'Brien, H. M. Kantarjian, J. Cortes, M. Beran, C. A. Koller, F. J. Giles, S. Lerner, and M. Keating
Results of the Fludarabine and Cyclophosphamide Combination Regimen in Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
March 1, 2001;
19(5):
1414 - 1420.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. R. Rai, B. L. Peterson, F. R. Appelbaum, J. Kolitz, L. Elias, L. Shepherd, J. Hines, G. A. Threatte, R. A. Larson, B. D. Cheson, et al.
Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia
N. Engl. J. Med.,
December 14, 2000;
343(24):
1750 - 1757.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Robak, J. Z. Blonski, M. Kasznicki, M. Blasinska-Morawiec, E. Krykowski, A. Dmoszynska, H. Mrugala-Spiewak, A. B. Skotnicki, W. Nowak, L. Konopka, et al.
Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial
Blood,
October 15, 2000;
96(8):
2723 - 2729.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. C. Gorin, E. Estey, R. J. Jones, H. I. Levitsky, I. Borrello, and S. Slavin
New Developments in the Therapy of Acute Myelocytic Leukemia
Hematology,
January 1, 2000;
2000(1):
69 - 89.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Bellosillo, N. Villamor, D. Colomer, G. Pons, E. Montserrat, and J. Gil
In Vitro Evaluation of Fludarabine in Combination With Cyclophosphamide and/or Mitoxantrone in B-Cell Chronic Lymphocytic Leukemia
Blood,
October 15, 1999;
94(8):
2836 - 2843.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Cheson, D. A. Vena, J. Barrett, and B. Freidlin
Second Malignancies as a Consequence of Nucleoside Analog Therapy for Chronic Lymphoid Leukemias
J. Clin. Oncol.,
August 1, 1999;
17(8):
2454 - 2454.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. R. Mauro, R. Foa, D. Giannarelli, I. Cordone, S. Crescenzi, E. Pescarmona, R. Sala, R. Cerretti, and F. Mandelli
Clinical Characteristics and Outcome of Young Chronic Lymphocytic Leukemia Patients: A Single Institution Study of 204 Cases
Blood,
July 15, 1999;
94(2):
448 - 454.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
